Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.